Transparency Life Sciences is betting on the wisdom of crowds when it comes to designing clinical trials. The company believes that it can address problems of falling R&D productivity that have plagued the pharmaceutical industry by using crowdsourcing and digital health technologies to design and conduct clinical trials more efficiently. We spoke to Tomasz Sablinski, CEO of Transparency, about what’s broken in drug development today, what his company is doing to change traditional approaches, and what need to do to prove its model actually works.

The Burrill Report (February 6, 2012): Fixing Drug Development with the Wisdom of Crowds (.MP3,14.48 Mb)